These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8846383)

  • 1. [The use of the hypoglycemic preparation gliquidone in patients with digestive organ diseases combined with diabetes mellitus].
    Degtiareva II; Lodianaia EV; Opanasiuk ND; Palladina OL
    Lik Sprava; 1995; (7-8):84-7. PubMed ID: 8846383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Multicenter study with gliquidone in type 2 diabetes mellitus].
    Kreze A; Vozár J; Rázus P; Lacko A; Málek Z; Putz Z
    Vnitr Lek; 1991; 37(9-10):761-7. PubMed ID: 1771808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glurenorm in the treatment of patients with non-insulin-dependent diabetes mellitus with diseases of the liver and bile ducts].
    Balabolkin MI; Nedosugova LV
    Probl Endokrinol (Mosk); 1993; 39(4):16-8. PubMed ID: 8415521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combined therapy with insulin/gliquidone (Glurenorm) in type 2 diabetes after treatment failure using oral antidiabetic agents].
    Podrouzková B; Krusová D
    Vnitr Lek; 1992 Oct; 38(10):963-7. PubMed ID: 1481374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A comparative evaluation of the effect of glurenorm and sulfonylurea preparations on the intravascular microcirculatory indices in type-II diabetes mellitus].
    Kakhnovskiĭ IM; Koroleva TV; Zakharchenko VN; Larionov SN
    Probl Endokrinol (Mosk); 1993; 39(2):7-9. PubMed ID: 8016059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of the effectiveness and tolerability of gliquidone in the treatment of diabetes mellitus type II].
    Iori I; Bosi E; Manicardi E; Del Din G; Dini FL; Portioli I
    Riv Eur Sci Med Farmacol; 1989 Jun; 11(3):277-83. PubMed ID: 2640049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An analysis of the causes of low-efficacy treatment in type-2 diabetes mellitus using sulfonylurea derivatives].
    Gendeleka GF
    Lik Sprava; 1996; (3-4):100-3. PubMed ID: 9035838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of glurenorm in patients with non-insulin-dependent diabetes mellitus and liver diseases].
    Dedov II; Demidova IIu; Pisklakov SV; Antokhin EA
    Probl Endokrinol (Mosk); 1993; 39(3):6-8. PubMed ID: 8058688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of short term hypoglycemic treatment with gliclazide and gliquidone on platelet function in patients with diabetes mellitus type II].
    Grzeszczak W; Strojek K
    Pol Tyg Lek; 1993 Apr; 48 Suppl 1():38-9. PubMed ID: 8516206
    [No Abstract]   [Full Text] [Related]  

  • 10. [Different clinical patterns of secondary drug failure in diabetes mellitus type II patients and their significance for diagnosis of secondary sulfonamide resistance].
    Gendeleka GF
    Lik Sprava; 2001; (3):158-9. PubMed ID: 11560011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical experience with Glurenorm in type 2 diabetics with renal insufficiency].
    Rybka J; Gregorová A; Zmydlená A
    Vnitr Lek; 1988 Aug; 34(8):786-92. PubMed ID: 3176368
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral hypoglycemic agents in type II diabetes mellitus.
    Lubbos H; Miller JL; Rose LI
    Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
    Fasching P
    Diabetologia; 1998 Jun; 41(6):743-4. PubMed ID: 9662063
    [No Abstract]   [Full Text] [Related]  

  • 14. Treating type 2 diabetes: targeting the many causative factors.
    Sutherland JE; Hoehns JD
    J Fam Pract; 2004 May; 53(5):376-88. PubMed ID: 15125823
    [No Abstract]   [Full Text] [Related]  

  • 15. [Gliquidone--opinions from the international literature].
    Krzyzanowska-Swiniarska B; Czekalski S; Fuchs H; Gruszczyńska M
    Pol Tyg Lek; 1993 Apr; 48 Suppl 1():40-1. PubMed ID: 8516207
    [No Abstract]   [Full Text] [Related]  

  • 16. [Glurenorm a new peroral antidiabetic agent belonging to the group of sulfonylurea compounds].
    Grujić M; Rizvanbegović B; Perinović M; Perinović ID
    Med Arh; 1976; 30(2):119-21. PubMed ID: 971371
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical evaluation of gliquidone--short acting sulfonylurea derivative--comparison with glibenclamide and gliclazide].
    Rupprecht E; König E; Limmer J
    Pol Tyg Lek; 1993 Apr; 48 Suppl 1():31-2. PubMed ID: 8516203
    [No Abstract]   [Full Text] [Related]  

  • 18. Pioglitazone + glimepiride: a combination product to avoid.
    Prescrire Int; 2007 Aug; 16(90):145. PubMed ID: 17724836
    [No Abstract]   [Full Text] [Related]  

  • 19. The effects of glurenorm on plasma glucose and lipids in patients with type 2 diabetes mellitus.
    Chou SC; Chen KW; Huang CC; Lin KD; Hwang JS; Lin JD
    Chang Gung Med J; 2000 Aug; 23(8):480-4. PubMed ID: 11039250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulphonylureas in the treatment of non-insulin-dependent diabetes.
    Ferner RE; Alberti KG
    Q J Med; 1989 Nov; 73(271):987-95. PubMed ID: 2695959
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.